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Abstract
Background: Reports on metabolic syndrome in nephroblastoma and neuroblastoma survivors are scarce. Aim was to
evaluate the occurrence of and the contribution of treatment regimens to the metabolic syndrome.
Patients and Methods: In this prospective study 164 subjects participated (67 adult long-term nephroblastoma survivors
(28 females), 36 adult long-term neuroblastoma survivors (21 females) and 61 control subjects (28 females)). Controls were
recruited cross-sectionally. Waist and hip circumference as well as blood pressure were measured. Body composition and
abdominal fat were assessed by dual energy X-ray absorptiometry (DXA-scan). Laboratory measurements included fasting
triglyceride, high density lipoprotein-cholesterol (HDL-C), glucose, insulin, low-density lipoprotein-cholesterol (LDL-C) and
free fatty acids (FFA) levels.
Results: Median age at follow-up was 30 (range 19–51) years in survivors and 32 (range 18–62) years in controls. Median
follow-up time in survivors was 26 (6–49) years. Nephroblastoma (OR= 5.2, P,0.0001) and neuroblastoma (OR 6.5, P,0.001)
survivors had more components of the metabolic syndrome than controls. Survivors treated with abdominal irradiation had
higher blood pressure, triglycerides, LDL-C, FFA and lower waist circumference. The latter can not be regarded as a reliable
factor in these survivors as radiation affects the waist circumference. When total fat percentage was used as a surrogate
marker of adiposity the metabolic syndrome was three times more frequent in abdominally irradiated survivors (27.5%) than
in non-irradiated survivors (9.1%, P = 0.018).
Conclusions: Nephroblastoma and neuroblastoma survivors are at increased risk for developing components of metabolic
syndrome, especially after abdominal irradiation. We emphasize that survivors treated with abdominal irradiation need
alternative adiposity measurements for assessment of metabolic syndrome.
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Introduction
Survival of childhood cancer has increased significantly over the
past few decades, leading to increased recognition and knowledge
of late effects. As treatment of childhood cancer is administered in
a growing and developing individual, organs and tissues might be
affected in a different and more severe way than in adults. The
mean five-year survival for nephroblastoma and neuroblastoma
survivors is 92% and 55%, respectively [1,2]. Although endocrine
late sequelae of pediatric cancer treatment are reported
[3,4,5,6,7], studies in nephroblastoma and neuroblastoma survi-
vors are scarce. Chemotherapy including anthracyclines, actino-
mycin and cyclophosphamide are administered in a considerable
subset of these survivors. Moreover, abdominal radiotherapy is
administered which includes the internal organs in the radiation
field. In addition, late effects after treatment in these survivors may
be aggravated by the removal of the affected organ. Subsequently,
development of the metabolic syndrome may occur. The Child-
hood Cancer Survivor Study found exposure to total body
irradiation or abdominal plus chest irradiation to be associated
with components of the metabolic syndrome such as dyslipidemia,
arterial hypertension and diabetes [8]. In addition, increased
prevalence of hypertension after abdominal irradiation was
observed in a study including 62 nephroblastoma survivors [9]
and increased prevalence of cardiovascular events after abdominal
irradiation was reported in a study including 185 nephroblastoma
survivors [10].
Metabolic syndrome is known to increase the risk for diabetes
and cardiovascular diseases [11,12]. Adipose tissue, or more
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specifically visceral fat, which is located around the internal
organs, plays a central role in the pathophysiology of metabolic
syndrome. Adipose tissue has been recognized as a highly active
metabolic organ involved in the production of several hormones
[13]. Excess of visceral fat is strongly correlated with cardiovas-
cular diseases, type 2 diabetes, insulin resistance and inflammatory
diseases [14,15,16,17]. The easiest way to measure visceral fat is
by measuring waist circumference. However, survivors of specific
cancer types such as nephroblastoma and neuroblastoma suffer
from scarred abdominal areas as a result from surgery and truncal
soft tissue hypoplasia caused by abdominal irradiation [18,19,20].
It is conceivable that these anatomical derangements induce
incorrect interpretation of abdominal adiposity. Subsequently,
although this issue has never been raised in childhood cancer
survivor studies, underscoring of the frequency of the metabolic
syndrome may occur.
Metabolic syndrome is defined for use in a clinical setting,
however other metabolic parameters such as measures of insulin
resistance and lipids provide additional information about
cardiovascular risk. Our primary objective was to evaluate the
frequency of (the components of) metabolic syndrome and
associated measures of insulin resistance and dyslipidemia in adult
long-term childhood nephroblastoma and neuroblastoma survi-
vors in comparison with a control group. Secondary, we aimed to
determine the influence of radiotherapy, chemotherapy and
surgery on the occurrence of metabolic syndrome.
Methods
Patients
All long-term ($5 years after cessation of treatment) adult
survivors of childhood nephroblastoma and neuroblastoma,
treated between 1961–2004 in the Erasmus MC-Sophia Chil-
dren’s Hospital that regularly visit the Late Effects outpatient clinic
were invited to participate in this prospective study. Written
informed consent was obtained according to the Helsinki
declaration and the study was approved by the local medical
ethical committee of the Erasmus Medical Centre, Rotterdam, the
Netherlands (NTR 2814). A controlgroup, consisting of siblings,
friends or neighbours, preferably of the same sex and within an
age range of five years of the survivor, was cross-sectionally
recruited.
Methods
Disease and treatment data were obtained from our local
database. Baseline data regarding weight, height and BMI at
diagnosis were extracted from the medical records. Data regarding
(partial) nephrectomy and (partial) unilateral adrenalectomy were
confirmed from pathological reports. Abdominal irradiation was
categorized according to location, i.e.: A) spine plus 1.5 cm on the
right and on the left hemi-abdomen, B) left hemi-abdomen
including the spine plus 1.5 cm on the right hemi-abdomen, C)
right hemi-abdomen including the spine plus 1.5 cm on the left
hemi-abdomen, D) total abdomen. Consequently, the following
categories according to organs involved in the radiation field were
created: Total pancreas (B+D), part of pancreas (A+C), total liver
(C+D) and part of liver (A+B) (Figure 1). Information regarding
smoking status, educational level, statin and antihypertensive
medication and diabetes was collected using a questionnaire.
Smoking status was defined as non-smoker, former smoker or
current smoker. Educational level was defined by the highest level
of educational attainment as selected from three categories based
on the Dutch educational system. Daily life physical activity was
assessed by the Short Questionnaire to Assess Health-enhancing
physical activity (SQUASH) [21]. Baseline characteristics are
shown in Table 1. Height was measured to the nearest millimeter
using a Harpenden Stadiometer and weight was assessed wearing
underwear only to the nearest 0.1 kg with a standard clinical
balance. Body mass index (BMI) was calculated (weight(kg))/
(height(cm)2) [22] and expressed in standard deviation scores
(SDS) [23,24]. Waist and hip circumference were measured to the
nearest 1 cm, midway between last rib and the iliac crest and at
the maximum circumference of the buttocks, respectively [25].
Waist-hip-ratio was calculated. Blood pressure was measured with
the subject in sitting position after an hour of rest on the right arm
with the DinamapH Procare and was defined as the mean of three
measurements. The metabolic syndrome is a constellation of
insulin resistance, adiposity, hypertension and dyslipidemia.
According to the revised National Cholesterol Education Pro-
gram/Adult Treatment Panel III (NCEP/ATP III) criteria,
participants with at least three of the following components were
diagnosed with metabolic syndrome: Waist circumference (as
a proxy for visceral fat) .102 cm in males or .88 cm in females;
triglycerides $1.7 mmol/l or treatment for dyslipidemia; high
density lipoprotein-cholesterol (HDL-C) ,1.03 mmol/l in males
or ,1.30 mmol/l in females; fasting plasma glucose (as a measure
of insulin resistance) $5.6 mmol/l or treatment for type 2
diabetes; blood pressure $130/85 mmHg or treatment for
hypertension [26]. Data on total body fat mass (kg), lean body
mass (kg) and percentage of body fat were retrieved from dual
energy X-ray absorptiometry (DXA, GE Lunar Prodigy, USA),
which was performed in survivors only. In addition, visceral fat
percentage was calculated from intra-abdominal fat (kg) and total
fat (kg) using the DXA scan [27]. Values for lean body mass and
total fat percentage were compared with normal Dutch reference
values and calculated as SDS [28].
Laboratory Measurements
Fasting blood samples were obtained from an intravenous-
cannula before 10:00 a.m. Serum values of triglyceride (mmol/l),
HDL-C (mmol/l), LDL-C (mmol/l), glucose (mmol/l) and free
fatty acids (FFA) (mmol/l) were measured using an enzymatic
in vitro assay (Roche Diagnostics, Mannheim, Germany). The
intra- and interassay coefficients of variation (CV) were ,2% and
,3% for triglycerides, ,1% and ,2% for HDL-C, ,1% and
,2% for LDL-C,,2% and,2% for glucose and,2% and,3%
for FFA. Serum insulin (pmol/l) and serum cortisol (nmol/l) levels
were measured using a chemi-luminescence-based immunoassay
(Immulite 2000, Siemens DPC, Los Angeles, CA, USA). Intra-
and interassay CV were ,6% and ,7% for insulin and ,7% and
,15% for cortisol. Homeostatic model assessment (HOMA), that
quantifies insulin resistance and beta cell function, was calculated
[29]. The HOMA authors used data from physiological studies to
develop mathematical equations describing glucose regulation as
a feedback loop. The authors have tested HOMA extensively
against other measures of insulin resistance (or its reciprocal,
insulin sensitivity) and b-cell function [30,31,32]. Modification of
Diet in Renal Disease (MDRD) study equation was calculated as
a measurement of glomerul filtration rate [33,34].
Statistics
Statistical analyses were performed with the Statistical Package
for Social Sciences (SPSS 17.0, Chicago, IL, USA). P-values
,0.05 (two-tailed) were considered statistically significant. In-
dependent Sample T-tests were used to compare results in
survivors and controls and in subgroups. Metabolic syndrome
and its separate components was evaluated with Chi-squared tests,
all subjects were included. When assessing the metabolic
Metabolic Syndrome after Childhood Cancer
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syndrome, information can be lost as outcomes are dichotomized.
Metabolic syndrome is designed for use in clinical settings but for
research purposes the use of continuous variables provides more
information. Therefore multiple linear regression analyses were
performed with the outcome parameters glucose, triglycerides,
HDL-C, waist circumference, systolic and diastolic blood pressure
(components of metabolic syndrome) and insulin, HOMA, LDL-
C, FFA (parameters considered associated with metabolic
syndrome) as dependent variables. Glucose, insulin, HOMA and
triglycerides levels were normally distributed after log-transforma-
tion and were expressed in percentages. Logistic regression
analysis was performed with the outcome parameter metabolic
syndrome (yes/no) as dependent variable and ordinal regression
analysis was performed with the number of components of
metabolic syndrome as dependent variable. For multiple linear
regression analyses subjects treated for diabetes were excluded
when evaluating glucose, insulin and FFA; subjects treated for
hypertension were excluded when evaluating blood pressure;
subjects treated for dyslipidemia were excluded when evaluating
triglycerides, HDL-C and LDL-C. All models were corrected for
age and sex. When the P-value was ,0.200 for the possible
confounders educational level, BMI, smoking and physical
activity, these confounders were kept in the subsequent models.
In model 1 the effects of the diagnoses (dummy variables) were
evaluated. In model 2–4 the effects of chemotherapy, nephrecto-
my, adrenalectomy and abdominal radiotherapy (dummy vari-
ables) were evaluated. Additionally, the effects of renal function (as
measured by MDRD) and adrenal function (as measured by basal
cortisol) were evaluated in model 2. Controls were indicated as not
treated for treatment variables. We included SDS for total
percentage fat $2 as a surrogate adiposity component for
metabolic syndrome. Frequency of SDS $2 for total percentage
fat was compared between survivors treated with and without
abdominal radiotherapy.
Results
Survivors and Controls
In this study we included 164 subjects, i.e. 103 adult long-term
survivors of nephroblastoma and neuroblastoma and 61 control
subjects. Out of 88 adult long-term survivors of nephroblastoma
who were alive and living in the Netherlands, 67 (28 females)
participated (six were lost to follow-up, two were not able to visit
the outpatient clinic at the appointed time and 13 refused).
Median age was 30.2 (range 18.8–50.8) years and median follow-
up time was 26.2 (6.4–48.9) years. Survivors of neuroblastoma
stage 4 s who had not received any previous treatment were
excluded from this study. Out of 55 remaining neuroblastoma
Figure 1. The black box indicates a schematic interpretation of the radiation field. A Part of pancreas (i.e. head and part of tail) and part of
liver in radiation field B Total pancreas (i.e. head and tail) and part of liver in radiation field C Part of pancreas (i.e. head and part of tail) and total liver
in radiation field D Total pancreas (i.e. head and tail) and total liver in radiation field Categories: B+D Total pancreas in radiation field A+C Part of
pancreas in radiation field C+D Total liver in radiation field A+B Part of liver in radiation field Original figure was retrieved from http://openlearn.
open.ac.uk.
doi:10.1371/journal.pone.0052237.g001
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survivors, 36 (21 females) participated (five were lost to follow-up,
three were pregnant at the time of the study and six refused).
Median age was 29.6 (20.4–46.2) years and median follow-up time
was 27.8 (15.0–44.4) years. Survivors that did not participate were
not different from participating survivors with respect to baseline
characteristics (data not shown).
Fifty-eight percent of survivors had a sibling or friend willing to
participate, resulting in 61 participating control subjects (28
females). Thirty-seven control subjects were siblings and 24 were
partners/friends. Main reason for control-subjects not to partic-
ipate was that they had to take a day off work. Baseline and
treatment characteristics are shown in Table 1.
Insulin Resistance
High fasting glucose (or treatment) was present in 14% of
controls, 22% of nephroblastoma and 20% of neuroblastoma
survivors (Table 2). After adjusting for confounders, glucose levels
were lower after adrenalectomy (b=28.7%, P= 0.001). Adding
MDRD (P= 0.364) and basal cortisol (P = 0.038) to this model did
not change this resuls (glucose after adrenalectomy b=29.6,
P,0.001) (Table 3). Five survivors were treated for type 2 diabetes
at time of the study. Of these five survivors, four received
irradiation to the total pancreas and one received irradiation to
part of the pancreas. Survivors who received radiotherapy to the
total pancreas had higher glucose levels than controls (ß = 10.5,
P= 0.002). Insulin levels were not determined by diagnosis, type of
chemotherapy, surgery or radiotherapy field (Table 3), even after
adjusting for MDRD and basal cortisol.
After adjusting for age, sex, educational level, smoking and
BMI, HOMA was not significantly different between non-diabetic
survivors of nephroblastoma (ß = 16.4%, P=0.075) and neuro-
blastoma (ß24.0%, P= 0.70) and controls. HOMA was not
Table 1. Baseline characteristics of study participants.
Nephroblastoma Neuroblastoma Controls
N 67 36 61
Male/female 39/28 15/21 33/28
Age at follow-up (yrs) 30.2 (18.8–50.8) 29.6 (20.4–46.2) 31.8 (18.0–61.8)
Age at diagnosis (yrs) 3.3 (0.0–12.7) 0.8 (0.0–11.7) n.a.
Follow-up time* (yrs) 26.2 (6.4–48.9) 27.8 (15.0–44.4) n.a.
BMI (SDS)** 20.52 (21.21–0.13) 20.58 (21.99–0.16) 0.08 (20.51–0.68)
BMI at diagnosis (SDS)** 0.08 (20.63–0.80) 0.31 (20.61–0.74) n.a.
Physical activity score** 8280 (6660–12000) 7130 (5843–9005) 8330 (6570–11370)
Non smoker 66% 50% 53%
Former smoker 12% 19% 16%
Smoker 22% 31% 31%
Low educational level 21% 22% 16%
Medium educational level 36% 33% 48%
High educational level 43% 45% 36%
(Partial) adrenalectomy (N) 33/67 13/36 n.a.
(Partial) nephrectomy (N) 67/67 7/36 n.a.
Radiotherapy abdomen (N) 35/67 7/36 n.a.
Radiotherapy thorax (N) 0/67 2/36 n.a.
Radiotherapy neck (N) 0/67 1/36 n.a.
Radiotherapy spine (N) 0/67 1/36 n.a.
Cumulative dose radiotherapy (gy) 20 (15–40) 20 (10–30) n.a.
Chemotherapy (N) 59/67 31/36 n.a.
N TCD N TCD
Vincristin (mg/m2) 51 22.0 (6.0–93.0) 16 22.8 (5.0–65.0) n.a.
Actinomycin D (mg/m2) 48 10.9 (0.1–24.8) 0 n.a. n.a.
Anthracyclines (mg/m2) 18 250 (100–450) 12 210 (100–315) n.a.
Cyclophosphamide (mg/m2) 2 3825 (250–7400) 29 7350 (3150–45990) n.a.
Cisplatin (mg/m2) 0 0 6 450 (270–630) n.a.
Teniposide (mg/m2) 0 0 6 500 (300–700) n.a.
Dacarbazine (mg/m2) 2 14.7 (13.5–15.8) 0 0 n.a.
Iphosphamide (mg/m2) 2 33000 (30000–36000) 0 0 n.a.
Data expressed as median (range) unless specified otherwise.
*Time after cessation of treatment.
**Data expressed as median (interquartile range).
n.a.=not applicable, Gy = gray, TCD= total cumulative dose.
doi:10.1371/journal.pone.0052237.t001
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affected by nephrectomy, adrenalectomy or chemotherapy. Basal
cortisol was significantly associated with HOMA (P=0.015), but
MDRD was not (P = 0.087). Adding these confounders to Model 2
did not affect results for nephrectomy, adrenalectomy or
chemotherapy. Survivors who received radiotherapy to the total
pancreas area had higher HOMA levels than controls (ß = 27.0%,
P= 0.034), in contrast to survivors who received radiotherapy to
part of the pancreas (ß = 3.7%, P= 0.78).
Table 2. Prevalence of components of the metabolic syndrome in nephroblastoma and neuroblastoma survivors compared with
controls.
Controls Nephroblastoma P-value1 Neuroblastoma P-value2
(N=61) (N=67) (N=36)
Fasting glucose* 14% 22% 0.27 20% 0.49
Hypertension* 14% 39% 0.002 29% 0.081
Low HDL-C 20% 24% 0.66 29% 0.39
High Triglycerides* 11% 27% 0.031 18% 0.35
High LDL 21% 31% 0.20 31% 0.32
High Waist** 10% 6% 0.44 12% 0.73
High % total body fat n.a. 15% n.a. 19% n.a.
*Or treatment.
**Waist circumference is imprecise in irradiated survivors.
1Nephroblastoma survivors compared with controls.
2Neuroblastoma survivors compared with controls (Chi-squared test). All subjects are included. Frequency of fasting glucose does not include one survivor with
diabetes type 1.
doi:10.1371/journal.pone.0052237.t002
Table 3. Influence of treatment components and diagnosis on parameters.
Glucose (%)1
Triglycerides
(%)2
HDL-C (mmol/
l)3
LDL-C (mmol/
l)2 Insulin (%)4 FFA (mmol/l)5
Model N 152* 149** 154** 153** 150* 151*
b P b P b P b P b P b P
1 Controls (N = 61) ref ref ref ref ref ref ref ref ref ref ref ref
Nephroblastoma (N = 67) 22.9 0.24 30.2 0.001 20.05 0.36 0.16 0.22 22.4 0.132 0.02 0.53
Neuroblastoma (N = 36) 21.7 0.55 12.9 0.24 20.10 0.105 0.44 0.004 28.1 0.60 0.05 0.29
2 Controls (N = 61) ref ref ref ref ref ref ref ref ref ref ref ref
Chemotherapy (N = 90) 1.8 0.55 28.3 0.009 20.12 0.054 0.45 0.003 27.6 0.139 0.05 0.28
Nephrectomy (N = 74) 5.3 0.47 22.3 0.83 0.07 0.27 20.40 0.014 18.8 0.33 20.13 0.005
Adrenalectomy (N = 49) 28.7 0.001 210.6 0.24 20.06 0.31 0.00 1.00 220.1 0.152 0.04 0.32
Rx abdomen (N = 42) 2.3 0.108 33.8 0.005 0.02 0.71 0.32 0.049 210.6 0.53 0.16 ,0.001
3 Controls (N = 61) ref ref ref ref ref ref ref ref ref ref ref ref
Pancreas – part (N = 15) 3.9 0.28 19.7 0.159 0.09 0.23 0.46 0.018 23.7 0.85 0.09 0.121
Pancreas – total (N = 27) 10.5 0.002 44.8 0.002 20.07 0.30 0.22 0.23 20.1 0.30 0.23 ,0.001
4 Controls (N = 61) ref ref ref ref ref ref ref ref ref ref ref ref
Liver – part (N = 19) 9.5 0.013 39.1 0.015 20.09 0.28 0.30 0.151 16.9 0.46 0.17 0.002
Liver – total (N = 23) 6.3 0.056 28.4 0.030 0.05 0.45 0.35 0.044 5.0 0.78 0.16 0.001
*subjects with treatment for diabetes excluded.
**subjects with treatment for dyslipidemia excluded.
1Corrected for age, sex, BMI, physical activity.
2Corrected for age, sex, BMI, smoking, physical activity.
3Corrected for age, sex, BMI, smoking.
4corrected for age, sex, SES, BMI.
5corrected for age, sex, physical activity. Glucose, insulin, HOMA and triglycerides levels were normally distributed after log-transformation and were expressed in
percentages. ref = reference value (control subjects).
Multiple linear regression analyses were performed using the following strategy: Model 1: the effects of both diagnoses (dummy variables) were added. Model 2: the
effects of chemotherapy, nephrectomy, adrenalectomy, abdominal radiotherapy (dummy variables) were added. Additional linear regression analyses were performed
according to the following strategy: Model 3: the effects of radiotherapy to the total pancreas and on part of the pancreas (Figure 1) (dummy variables) were added.
Model 4: the effect of radiotherapy on the total liver and on part of the liver (Figure 1) (dummy variables) were added. Model 3 and 4 were additionally corrected for the
treatment components that were significant in Model 2. P-values indicate the significance of the difference with control subject.
doi:10.1371/journal.pone.0052237.t003
Metabolic Syndrome after Childhood Cancer
PLOS ONE | www.plosone.org 5 December 2012 | Volume 7 | Issue 12 | e52237
Blood Pressure
Thirty-nine percent of nephroblastoma survivors had arterial
hypertension or treatment for hypertension versus 29% of
neuroblastoma survivors and 14% of controls (Table 2). After
adjusting for age, sex, BMI and smoking, both nephroblastoma
and neuroblastoma survivors had higher systolic (b=5.6,
P = 0.007 and b=7.1, P= 0.003, respectively) and diastolic
(b=4.8, P= 0.001 and b=6.0, P= 0.001, respectively) blood
pressure levels than controls. Abdominal radiotherapy was
associated with higher systolic (b=6.1, P = 0.021) and diastolic
(b=4.9, P = 0.011) blood pressure. After adding MDRD and basal
cortisol to the model abdominal radiotherapy was still associated
with systolic (b=6.2, P= 0.019) and with diastolic (b=4.8,
P = 0.011) blood pressure. Chemotherapy only was associated
with higher systolic blood pressure (b=4.9, P= 0.041), also after
adding MDRD and basal cortisol to this model (b=5.2,
P = 0.040).
Dyslipidemia
High triglyceride levels or treatment for dyslipidemia was
registered in 27% of nephroblastoma survivors, 18% of neuro-
blastoma survivors and 11% in controls (Table 2). After adjusting
for confounders, nephroblastoma survivors had higher triglyceride
levels (b=30.2, P = 0.001), which seemed to be determined by
abdominal radiotherapy (b=33.8, P= 0.005) and chemotherapy
only (b=28.3, P = 0.009) (Table 3). Basal cortisol was significantly
associated with triglycerides (P,0.001) and MDRD was not
(P = 0.225), however this did not change the results (abdominal
radiotherapy b=36.1, P= 0.001) and chemotherapy only
b=27.9, P = 0.007). Survivors who received radiotherapy to the
total pancreas had significantly higher triglyceride levels
(b=44.8%, P= 0.002) than controls, in contrast to survivors
who received radiotherapy to part of the pancreas (b=19.7%,
P=0.159) (Table 3). Diagnosis, treatment components and
radiotherapy field did not affect the HDL levels (Table 3), which
remained the same after adjusting for MDRD and basal cortisol.
After adjusting for confounders, LDL-C levels were higher in
neuroblastoma survivors (b=0.44, P= 0.004). Chemotherapy only
(b=0.45, P= 0.003) and abdominal radiotherapy (b=0.32,
P = 0.049) were positively associated with LDL-C levels, whereas
nephrectomy was negatively associated with LDL-C levels
(b20.40, P= 0.014). Basal cortisol was significantly associated
with LDL-C (P= 0.003) and MDRD was not (P = 0.851), however
this did only slightly change these results (chemotherapy only
b=0.48, P= 0.002), abdominal radiotherapy b=0.31, P = 0.050,
nephrectomy b=0.42, P= 0.011). Survivors who received radio-
therapy to the total liver had higher LDL-C levels (b=0.35,
P = 0.044) than controls (Table 3).
After adjusting for confounders, abdominal radiotherapy was
positively associated with higher FFA levels (b=0.16, P,0.001),
also after correction for MDRD and basal cortisol (b=0.17,
P,0.001) whereas nephrectomy was negatively associated with
FFA levels (b=20.13, P = 0.005), also after correction for MDRD
and basal cortisol (b=0.14, P= 0.003).
Survivors who received radiotherapy to the total pancreas had
significantly higher FFA levels than controls (b=0.23, P,0.001),
in contrast to survivors who received radiotherapy to only part of
the pancreas (b=0.09, P= 0.121) (Table 3).
Adiposity Measurements
Baseline data regarding weight, height and BMI at diagnosis
were available in 84 out of 103 survivors. Median BMI at
diagnosis in nephroblastoma survivors was 20.52 (interquartile
range (21.21–0.13) and in neuroblastoma survivors 20.58
(interquartile range 21.99–0.16). After correction for age and
sex, nephroblastoma survivors had a smaller waist circumference
(b=24.7 cm, P,0.001) than controls. After additional correction
for BMI, low waist circumference was associated with abdominal
radiotherapy (b=25.6, P,0.001) but not with diagnosis or
surgery. This effect remained the same after adjusting for MDRD
and basal cortisol. It is conceivable that this abnormal waist
circumference is determined by anatomical derangements due to
abdominal irradiation. Therefore, suggorate markers for adiposity
were included in the analyses. After adjusting for age, sex and
BMI, abdominal radiotherapy was associated with a lower waist/
hip ratio (ß20.05, P,0.001) and with a lower abdominal fat/tot
body fat ratio (ß =21.9, P,0.001) but not with total body fat
percentage (ß = 1.4, P= 0.29).
High waist circumference was present in 14% of the survivors
treated without abdominal radiotherapy and in 2% of the
survivors treated with abdominal radiotherapy (P= 0.020). Using
total body fat (as measured by DXA-scan) as a surrogate marker
for adiposity, 9% of the survivors treated without abdominal
radiotherapy was categorized as adipose versus 28% of the
survivors treated with abdominal radiotherapy (P= 0.018).
Metabolic Syndrome
Prevalence of metabolic syndrome according to the NCEP
criteria was not significantly different between nephroblastoma
and neuroblastoma survivors and controls (Figure 2). After
adjusting for age, sex, educational level and BMI, odds ratios
(OR) for the frequency of metabolic syndrome as compared with
controls were still not significant (OR for nephroblastoma
survivors 4.3, P= 0.093, OR for neuroblastoma survivors 2.7,
P= 0.38). However, OR for the number of components of the
metabolic syndrome were 5.2 (P,0.001) in nephroblastoma and
6.5 in neuroblastoma (P,0.001) survivors.
Subsequently, total fat percentage as measured by DXA scan
was used as a surrogate marker for the adiposity component of
metabolic syndrome. Metabolic syndrome was almost three times
more frequent in abdominally irradiated survivors (28%) than in
non-irradiated survivors (9%, P= 0.018) (Figure 3).
Discussion
In the present study we show that abdominal irradiation is the
main determinant of metabolic syndrome in long-term survivors of
nephroblastoma and neuroblastoma, which was mainly due to
hypertension, adiposity and dyslipidemia. Metabolic syndrome
occurred three times more often in abdominally irradiated
survivors, which is significant, especially when the relatively young
age of the survivors and the fact that the incidence of
cardiovascular diseases increases with age is taken into account
[35].
In the current study, hypertension and dyslipidemia in
nephroblastoma and neuroblastoma survivors were mainly de-
termined by previously administered abdominal irradiation. This
is consistent with findings of the Childhood Cancer Survivor Study
as we described in the introduction of this manuscript. We
hypothesize that the effect of abdominal radiotherapy on de-
velopment of (components of the) metabolic syndrome may be due
to radiation induced damage on individual organs. Therefore, we
categorized patients according to administered radiation field.
Although HOMA and insulin levels were not different from
controls in the non-diabetic survivors, we show that radiotherapy
involving both head and tail of the pancreas influenced the
occurrence of dyslipidemia and insulin resistance significantly. The
pancreas has always been considered as relatively insensitive to
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radiation [36,37], however similar to the recent report of de
Vathaire et al. [38], our findings indicate that the pancreas is an
organ at risk during radiation therapy. This probably results from
radiation induced apoptosis of pancreatic beta cells, and conse-
quently to decreased insulin production, the thereby induced
hyperglycemia, elevated FFA levels and hypertriglyceridemia and
insulin resistance. We also show that abdominal irradiation
involving the complete liver influences LDL-C levels, in contrast
to irradiation involving only part of the liver. These results indicate
that non-irradiated liver and non-irradiated pancreas fields may
have the capacity to compensate for impaired liver and pancreas
function of the irradiated fields. Although we were only able to
Figure 2. Components of the metabolic syndrome in nephroblastoma and neuroblastoma survivors. Frequency of metabolic syndrome
determined according to the definition of the NCEP. Each group in total (0, 1, 2, $3 components) equals 100%.
doi:10.1371/journal.pone.0052237.g002
Figure 3. Components of the metabolic syndrome in survivors treated with and without abdominal irradiation. Frequency of the
metabolic syndrome determined according to the definition of NCEP but instead of waist circumference, total percentage fat was used as an
alternative marker for adiposity. Prevalence of metabolic syndrome ($3 components) in abdominally irradiated survivors is significantly higher than
in controls (P = 0.018) (Chi-squared test). Each group in total (0, 1, 2, $3 components) equals 100%.
doi:10.1371/journal.pone.0052237.g003
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categorize radiation fields, these single centre study results
emphasize the need for studies in larger cohorts of childhood
cancer survivors involving detailed radiation dosimetry, as this
might help to unravel the mechanism behind the development of
metabolic syndrome.
This is the first study that acknowledges the need for surrogate
markers for adiposity in survivors after abdominal irradiation with
a deformed abdominal area. We show that the measurement of
total body fat probably provides a more reliable measurement of
adiposity than waist circumference in abdominally irradiated
survivors. It should be considered that abdominal fat is a better
predictor of visceral fat than total body fat, however this needs the
use of a computerised tomography (CT) or Magnetic Resonance
Imaging (MRI) scan, which is expensive, time-consuming and
undesirable in childhood cancer survivors who have often already
been exposed to teratogenic treatments. Clinicians and researchers
however need to be aware of the underestimation of adiposity and
metabolic syndrome and, subsequently, the risk for cardiovascular
diseases, when using waist circumference as a parameter in this
specific subgroup.
Besides abdominal radiotherapy, we observed chemotherapy
only to be associated with higher systolic blood pressure and
dyslipidemia. Although the exact mechanism remains to be
elucidated, it might well be that chemotherapeutic agents damage
the vascular endothelium, resulting in vascular alterations.
Furthermore, we found nephrectomy to be associated with
lower LDL-C and FFA levels, whereas adrenalectomy was
associated with lower glucose levels. Both types of surgery thus
do not seem to increase the risk for development of metabolic
syndrome. We additionally adjusted for glomerular filtration rate
and for basal cortisol to be able to analyze the direct effect renal
and adrenal function on the outcome parameters. Similar to what
we previously showed, basal cortisol levels were associated with
insulin resistance and dyslipidemia [39]. We found no effect of
glomerular filtration rate on our outcome parameters. This
indicates that the effect of nephrectomy on lower FFA and
LDL-C levels, is not determined by decreased renal function. In
our study, abdominal ultrasounds performed as part of clinical
follow-up did not show structural defects in the survivors. In future
studies, imaging modalities might however provide extra in-
formation, although it needs to be considered that size of kidney or
adrenal gland is not necessarily related to function. Specific studies
evaluating the correlation between imaging modalities and
function of organs however are of interest and might identify
practical tools for the future.
Although our study was limited by small sample sizes due to
therapy subgroups, we are the first to report on metabolic
syndrome and associated measures in survivors of nephroblastoma
and neuroblastoma. To be able to increase power, we recommend
accrual of higher number of control subjects for future studies.
Furthermore, to evaluate the effects of baseline characteristics on
the outcome variables, we performed a subanalysis and found BMI
at diagnosis not to be associated with BMI at follow-up, or with
waist circumference, diastolic blood pressure, triglycerides and
HDL-C. This indicates that components of the metabolic
syndrome in childhood cancer survivors are determined by
treatment factors and less by baseline patients characteristics.
Higher BMI at diagnosis was associated with lower blood pressure
and lower glucose levels at follow-up, which indicates that the
results we described in our paper might be underestimated, but are
unlikely to be overestimated.
In conclusion, our study demonstrated that nephroblastoma and
neuroblastoma survivors are at increased risk for developing
(components of) metabolic syndrome, and that abdominal
radiotherapy is the main determinant of its occurrence. Our
findings indicate that the pancreas and the liver are organs at risk
for damage due to radiation therapy. Consequently, when
planning treatment, a radiation dose as low as possible including
the smallest field, should be administered. This is especially
applicable for children treated for neuroblastoma and nephro-
blastoma. Surrogate markers for adiposity, such as total body fat,
should be included in future studies in order to get insight in the
true frequency of metabolic syndrome after abdominal irradiation.
Prospective studies in large cohorts including radiation dosimetry
are necessary to be able to unravel the underlying mechanisms
behind the increased risk for developing components of metabolic
syndrome after abdominal radiotherapy.
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